While pembrolizumab received United States Food and Drug Administration approval for advanced cervical cancer in June 2018, no meta-analysis has evaluated the impact of PD-1 inhibitors on survival outcomes across the entire spectrum of advanced or recurrent uterine cancers, encompassing both endometrial and cervical types. This evidence concerns the gene PDCD1 and cervical cancer.